| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5767251 | EMD SERONO | Recombinant heterodimeric human fertility hormones, and methods, cells, and vectors and DNA for the production thereof |
Jun, 2015
(8 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5767251 | EMD SERONO | Recombinant heterodimeric human fertility hormones, and methods, cells, and vectors and DNA for the production thereof |
Jun, 2015
(8 years ago) | |
| US6706681 | EMD SERONO | HCG liquid formulations |
Mar, 2021
(3 years ago) | |
Ovidrel is owned by Emd Serono.
Ovidrel contains Choriogonadotropin Alfa.
Ovidrel has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Ovidrel are:
- US5767251
- US6706681
- US5767251
Ovidrel was authorised for market use on 20 September, 2000.
Ovidrel is available in injectable;subcutaneous, injectable;injection dosage forms.
The generics of Ovidrel are possible to be released after 16 March, 2021.
Drugs and Companies using CHORIOGONADOTROPIN ALFA ingredient
Market Authorisation Date: 20 September, 2000
Treatment: NA
Dosage: INJECTABLE;SUBCUTANEOUS; INJECTABLE;INJECTION
More Information on Dosage
OVIDREL family patents
